Novel treatment strategy with direct renin inhibition against heart failure

Panminerva Medica

Volumn 52, Issue 1, 2010, Pages 41-51

  Quercioli, A ^a,b   Mach, F ^b   Montecucco, F ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Heart failure, diastolic; Heart failure, systolic; Renin angiotensin system

Indexed keywords

RENIN;

DRUG ANTAGONISM; HEART FAILURE; HUMAN; PATHOPHYSIOLOGY; REVIEW;

HEART FAILURE; HUMANS; RENIN;

EID: 77954735340     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (89)

1. Knim H, Abraham WT. Heart failure. Lancet 2009;373:941-955
2. Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW et al. Quantifying the heart failure epidemic: preva-lence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 2004;25:1614-1619
3. Davie AP, Francis CM, Love MP, CaruanaL, Starkey IR, Shaw TR et al. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ 1996;312:222.
4. White JA, Patel MR. The role of cardiovascular MRI in heart failure and the cardiomyopathies. Cardiol Clin 2007;25:71-95.
5. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005;293:1900-1905
6. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Due P et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-167
7. Packer M. Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure? Circulation 2003;108:2950-2953
8. Clerico A, Del Ry S, Maffei S, Prontera C, Emdin M, Giannessi D. The circulating levels of cardiac natriuretic hormones in healthy adults: effects of age and sex. Clin Chem Lab Med 2002;40:371-377
9. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating die scope of the heart failure epidemic. JAMA 2003;289:194-202.
10. Fischer M, Baessler A, Hense HW, Hengstenberg C, Muscholl M, Holmer Setal. Prevalence of left ventricular diastolic dysfunction in the community. Results from a Doppler echocardiographic-based survey of a population sample. Eur Heart J 2003;24:320-328
11. Krum H, Gilbert RE. Demographics and concomitant disorders in heart failure. Lancet 2003;362:147-158
12. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993;88:107-115
13. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007;93:1137-1146
14. MacDonald MR, Petrie MC, Hawkins NM, Petrie JR, Fisher M, McKelvie R et al. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J 2008;29:1224-1240
15. Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 2001;24:5-10.
16. Braunwald E, Rutherford JD. Reversible ischemic left ventricular dysfunction: evidence for the "hibernating myocardium". J Am Coll Cardiol 1986;8:1467-1470
17. Stevenson WG, Sweeney MO. Pharmacologic and nonpharmacologic treatment of ventricular arrhythmias in heart failure. Curr Opin Cardiol 1997;12:242-250
18. Chatterjee K, Rame JE. Systolic heart failure: chronic and acute syndromes. Crit Care Med 2008;36:S44-51.
19. Ng AC, Davis GM, Chow CM, Coats AJ, Sindone AP, Freedman B. Impact of sleep disordered breathing severity on hemodynamics, autonomic balance and cardiopulmonary functional status in chronic heart failure. Int J Cardiol. 2009; doi:10.1016/j.ijcard. 2008.11.191.
20. Krum H, Jelinek MV, Stewart S, Sindone A, Atherton JJ, Hawkes AL; CHF Guidelines Core Writers. Guidelines for the prevention, detection and management of people with chronic heart failure in Australia 2006. Med J Aust 2006;185:549-557
21. Thohan V, Patel S. The challenges associated with current clinical trials for diastolic heart failure. Curr Opin Cardiol 2009;24:230-238
22. Brilla CG, Maisch B, Weber KT. Myocardial collagen matrix remodelling in arterial hypertension. Eur Heart J 1992;13 Suppl D:24-32.
23. Wilson EM, Spinale FG. Myocardial remodelling and matrix metal-loproteinases in heart failure: turmoil within the interstitium. Ann Med 2001;33:623-634
24. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation 2002;105:1503-1508
25. Sciarretta S, Paneni F, Palano F, Chin D, Tocci G, Rubattu S et al. Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction. Clin Sci (Lond) 2009; 116:467-477
26. Dorn GW 2nd. Novel pharmacotherapies to abrogate postinfarction ventricular remodeling. Nat Rev Cardiol 2009;6:283-291
27. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006;86:747-803.
28. Montecucco F, Pende A, Mach F. The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. Mediators Inflamm 2009;2009:752406.
29. Dzau VJ, Ellison KE, Brody T, Ingelfinger J, Pratt RE. A comparative study of the distributions of renin and angiotensinogen messenger ribonucleic acids in rat and mouse tissues. Endocrinology 1987;120:2334-2338
30. Paul M, Wagner J, Dzau VJ. Gene expression of die renin-angiotensin system in human tissues. Quantitative analysis by the polymerase chain reaction. J Clin Invest 1993;91:2058-2064
31. Schiitz S, Le Moullec JM, Corvol P, Gasc JM. Early expression of all the components of the renin-angiotensin-system in human development. Am J Pathol 1996;149:2067-2079
32. von Lutterotti N, Catanzaro DF, Sealey JE, Laragh JH. Renin is not synthesized by cardiac and extrarenal vascular tissues. A review of experimental evidence. Circulation 1994;89:458-470
33. Danser AH, van Kesteren CA, Bax WA, Tavenier M, Derkx FH, Saxena PR et al. Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding. Circulation 1997;96:220-226
34. de Lannoy LM, Danser AH, van Kats JP, Schoemaker RG, Saxena PR, Schalekamp MA. Renin-angiotensin system components in the interstitial fluid of the isolated perfused rat heart. Local production of angiotensin I. Hypertension 1997;29:1240-1251
35. Jan Danser AH, Saris JJ. Prorenin uptake in the heart: a prerequisite for local angiotensin generation? J Mol Cell Cardiol 2002;34: 1463-1472
36. Nguyen G, Burckle' CA, Sraer JD. Renin/prorenin-receptor biochemistry and functional significance. Curr Hypertens Rep 2004;6: 129-132
37. Saris JJ, Derkx FH, De Bruin RJ, Dekkers DH, Lamers JM, Saxena PR et al. High-affinity prorenin binding to cardiac man-6-P/IGF-II receptors precedes proteolytic activation to renin. Am J Physiol Heart Ore Physiol 2001;280:H1706-15.
38. Saris JJ, van den Eijnden MM, Lamers JM, Saxena PR, Schalekamp MA, Danser AH. Prorenin-induced myocyte proliferation: no role for intracellular angiotensin JJ. Hypertension 2002;39:573-577
39. Nguyen G, Delarue F, Burckle' C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin JJ production and cellular responses to renin. J Clin Invest 2002;109:1417-1427
40. Peters J, Farrenkopf R, Clausmeyer S, Zimmer J, Kantachuvesiri S, Sharp MG et al. Functional significance of prorenin internalization in the rat heart. Ore Res 2002;90:1135-1141
41. Peters J, Schluter T, Riegel T, Peters BS, Beineke A, Maschke U et al. Lack of cardiac fibrosis in a new model of high prorenin hyperaldo-steronism. Am J Physiol Heart Ore Physiol 2009;297:H 1845-1852
42. Kumar R, Singh VP, Baker KM. The intracellular renin-angiotensin system in the heart. Curr Hypertens Rep 2009;11:104-110
43. Kumar R, Singh VP, Baker KM. The intracellular renin-angiotensin system: implications in cardiovascular remodeling. Curr Opin Nephrol Hypertens 2008;17:168-173
44. Kumar R, Boim MA. Diversity of pathways for intracellular angiotensin II synthesis. Curr Opin Nephrol Hypertens. 2009;18:33-39
45. Singh VP, Le B, Khode R, Baker KM, Kumar R. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocy-te apoptosis, oxidative stress, and cardiac fibrosis. Diabetes 2008;57:3297-3306
46. Dhalla NS, Saini-Chohan HK, Rodriguez-Leyva D, Elimban V, Dent MR, Tappia PS. Subcellular remodelling may induce cardiac dysfunction in congestive heart failure. Cardiovasc Res 2009;81:429-438
47. Wanka H, KeBler N, Ellmer J, Endlich N, Peters BS, Clausmeyer S et al. Cytosolic renin is targeted to mitochondria and induces apoptosis in H9c2 rat cardiomyoblasts. 2008;10.111l/j.l582-4934.2008.00448.x.
48. Flesch M, Schiffer F, Zolk O, Pinto Y, Rosenkranz S, Hirth-Dietrich C et al. Contractile systolic and diastolic dysfunction in renin-indu-ced hypertensive cardiomyopathy. Hypertension 1997;30:383-391
49. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006; 368:1449-1456
50. Wood JM, Maibaum J, Rahuel J, Grutter MG, Cohen NC, Rasetti V et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003;308:698-705.
51. Novartis, Pharmaceuticals Corporation. Tekturna, Aliskiren Tablets, (product information). East Hanover, NJ, 2007.
52. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002;39:E1-8.
53. Waldmeier F, Glaenzel U, Wirz B, Oberer L, Schmid D, Seiberling M et al. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos 2007;35:1418-1428
54. Wood JM, Schnell CR, Cumin F, Menard J, Webb RL. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens 2005;23: 417-426
55. Azizi M, Mdnard J, Bissery A, Guyenne TT, Bura-Riviere A, Vaidyanathan S et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the ATI receptor antagonist valsartan on the angiotensin U-renin feedback interruption. J Am Soc Nephrol 2004;15:3126-3133
56. Vaidyanathan S, Bigler H, Yeh C, Bizot MN, Dieterich HA, Howard D et al. Dole WP. Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment. J Clin Pharmacol 2007;47:192-200. (Pubitemid 46146485)
57. Dieterle W, Corynen S, Vaidyanathan S, Mann J. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther 2005;43:527-535
58. Dieterle W, Corynen S, Mann J. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol 2004;58:433-436
59. Vaidyanathan S, Camenisch G, Schuetz H, Reynolds C, Yeh CM, Bizot MN et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol 2008; 48:1323-1338
60. Lam S, Choy M. Aliskiren: an oral renin inhibitor for the treatment of hypertension. Cardiol Rev 2007;15:316-323
61. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang, Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005;111:1012-1018
62. Stanton A. Therapeutic potential of renin inhibitors in the management of cardiovascular disorders. Am J Cardiovasc Drugs 2003;3:389-394
63. Skeggs LT Jr, Kahn JR, Lentz K, Shumway NP. The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med 1957;106:439-453
64. Westermann D, Schmieder R, Schultheiss HP, Tschope C. Renin inhibitors, clinical experience. J Mol Med 2008;86:691-695
65. Westermann D, Riad A, Lettau O, Roks A, Savvatis K, Becher PM et al. Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension 2008;52:1068-1075
66. Sweet CS, Ludden CT, Frederick CM, Ribeiro LG. Hemodynamic effects of angiotensin and renin inhibition in dogs with acute left ventricular failure. Am J Med 1984;77:7-12.
67. Mento PF, Maita ME, Murphy WR, Holt WF, Wilkes BM. Comparison of angiotensin converting enzyme and renin inhibition in rats following myocardial infarction. J Cardiovasc Pharmacol 1993;21: 791-796
68. Fitzpatrick MA, Rademaker MT, Charles CJ, Yandle TG, Espiner EA, Dcram H et al. Comparison of the effect of renin inhibition and angiotensin-converting enzyme inhibition in ovine heart failure. J Cardiovasc Pharmacol 1992;19:169-175
69. Zhang Q, Kohara K, Qui H Y, Hiwada K. Comparative effects of three sites of renin-angiotensin blockade on the regression of left ventricular hypertrophy in spontaneously hypertensive rats. Am J Ther 1997;4: 199-202.
70. Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, Gratze P et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005;46:569-576
71. Nussberger J, Aubert JF, Bouzourene K, Pellegrin M, Hayoz D, Mazzolai L. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine. Hypertension 2008;51:1306-1311
72. Imanishi T, Tsujioka H, Ikejima H, Kuroi A, Takarada S, Kitabata H et al. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension 2008;52:563-572
73. Lu H, Rateri DL, Feldman DL, Charnigo Jr PJ, Fukamizu A, Ishida J et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest 2008; 118:984-993
74. Shagdarsuren E, Wellner M, Braesen JH, Park JK, Fiebeler A, Henke N et al. Complement activation in angiotensin U-induced organ damage. Ore Res 2005;97:716-724
75. Fischer R, Dechend R, Qadri F, Markovic M, Feldt S, Herse F et al. Dietary n-3 polyunsaturated fatty acids and direct renin inhibition improve electrical remodeling in a model of high human renin hypertension. Hypertension 2008;51:540-546
76. Sakoda M, Ichihara A, Kaneshiro Y, Takemitsu T, Nakazato Y, Nabi AH et al. (Pro)renin receptor-mediated activation of mitogen-activa-ted protein kinases in human vascular smooth muscle cells. Hypertens Res 2007;30:1139-1146
77. de Boer RA, Pokharel S, Flesch M, van Kampen DA, Suurmeijer AJ, Boomsma F et al. Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin U driven progression towards overt heart failure in homozygous TGR(mRen2)27. J Mol Med 2004;82:678-687
78. Feldt S, Batenburg WW, Mazak I, Maschke U, Wellner M, Kvakan H et al. Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 2008;51:682-688
79. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008;52:130-136
80. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003;42:1137-1143
81. Kiowski W, Beermann J, Rickenbacher P, Haemmerli R, Thomas M, Burkart F et al. Angiotensinergic versus nonangiotensinergic hemodynamic effects of converting enzyme inhibition in patients with chronic heart failure. Assessment by acute renin and converting enzyme inhibition. Circulation 1994;90:2748-2756
82. Neuberg GW, Kukin ML, Penn J, Medina N, Yushak M, Packer M. Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure. Am J Cardiol 1991;67:63-66
83. Seed A, Gardner R, McMurray J, Hillier C, Murdoch D, MacFadyen R et al. Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. Eur J Heart Fail 2007;9:1120-1127
84. Sever PS, Gradman AH, Azizi M. Managing cardiovascular and renal risk: the potential of direct renin inhibition. J Renin Angiotensin Aldosterone Syst 2009;10:65-76.
85. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M et al. Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology Eur Heart J 2005;26:1115-1140
86. McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008;1:17-24.
87. Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V et al. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009;119:530-537
88. Novartis, Efficacy and safety of aliskiren and valsartan versus placebo in patients stabilized following an acute coronary syndrome. [Internet]. http://www.clinicaltrials.gov/ct2/show/NCT00409578, [cited 2009, Aug 2].
89. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009;24:1663-1671